Interestingly, a recent study in 112 individuals with T2DM showed that the long-acting GLP1-RA dulaglutide (which has been previously shown to reduce the risk of major adverse cardiovascular events in T2DM [17]) improved RHI after 9-months of treatment but that this effect was not apparent at 3-months [18]. Here, GLP1R is linked to type 2 diabetes mellitus.